These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
68 related articles for article (PubMed ID: 2695186)
1. [Dose factors/time factors in chemotherapy]. Philip T; Bouffet E; Biron P; Brunat-Mentigny M Bull Cancer; 1989; 76(9):979-94. PubMed ID: 2695186 [No Abstract] [Full Text] [Related]
2. [Dose intensity in cancer chemotherapy: definition, average relative dose intensity and effective dose intensity]. Alberto P Bull Cancer; 1995; 82 Suppl 1():3s-8s. PubMed ID: 7626852 [TBL] [Abstract][Full Text] [Related]
3. The use of hematological growth factors to enable dose intensification in chemotherapy for soft tissue sarcomas. Liem GS; Verweij J Stem Cells; 1994 Jul; 12(4):402-8. PubMed ID: 7951007 [TBL] [Abstract][Full Text] [Related]
5. Review of the application of response surface methodology in the combination therapy of cancer. Carter WH; Wampler GL Cancer Treat Rep; 1986 Jan; 70(1):133-40. PubMed ID: 3943113 [No Abstract] [Full Text] [Related]
6. [Segidrin: a new-type antineoplastic agent]. Filov VA Vopr Onkol; 1994; 40(1-3):3-14. PubMed ID: 7701790 [No Abstract] [Full Text] [Related]
7. [Dose-effect of chemotherapy in bronchial small-cell cancer]. de Crevoisier R; le Cesne A; le Chevalier T Rev Mal Respir; 1997 Sep; 14(4):269-75. PubMed ID: 9411610 [TBL] [Abstract][Full Text] [Related]
9. Oxaliplatin (Eloxatin) for advanced colon cancer. Med Lett Drugs Ther; 2003 Jan; 45(1148):7-8. PubMed ID: 12571541 [No Abstract] [Full Text] [Related]
10. Use of dose-dense chemotherapy in the management of breast cancer. Norton L Clin Adv Hematol Oncol; 2006 Jan; 4(1):36-7. PubMed ID: 16562368 [No Abstract] [Full Text] [Related]
11. Chemotherapy for ovarian cancer: an evidence-based approach. Geisler JP; Manahan KJ; Wiemann MC Minerva Ginecol; 2004 Dec; 56(6):539-45. PubMed ID: 15729206 [TBL] [Abstract][Full Text] [Related]
12. Second-line chemotherapy in head and neck cancer: what should we expect? Büntzel J; Micke O Expert Rev Anticancer Ther; 2009 Mar; 9(3):269-73. PubMed ID: 19275504 [No Abstract] [Full Text] [Related]
13. [Current approaches to the use of radiotherapy in patients with non-small-cell lung cancer]. Goldobenko GV; Kanaev SV Vopr Onkol; 1998; 44(5):623-8. PubMed ID: 9884730 [No Abstract] [Full Text] [Related]
14. [Chemotherapy of cancer of the esophagus]. Seitz JF Bull Cancer; 1989; 76(9):995-1005. PubMed ID: 2695187 [No Abstract] [Full Text] [Related]
16. Average relative dose intensity and the impact on design of clinical trials. Hryniuk WM Semin Oncol; 1987 Mar; 14(1):65-74. PubMed ID: 3823917 [No Abstract] [Full Text] [Related]
17. Some considerations on the role of chemotherapy in individualization of cancer therapy. Tagnon HJ Strahlentherapie; 1984 Nov; 160(11):681-3. PubMed ID: 6506107 [No Abstract] [Full Text] [Related]
18. Invited commentary. Piehler JM Ann Thorac Surg; 2005 Oct; 80(4):1183-4. PubMed ID: 16181837 [No Abstract] [Full Text] [Related]
19. [Medical treatment of colorectal cancers: evaluation]. Pouillart P Ann Gastroenterol Hepatol (Paris); 1993 May; 29(3):133-6. PubMed ID: 8517630 [No Abstract] [Full Text] [Related]
20. Dose-dense chemotherapy for primary breast cancer. Kümmel S; Rezai M; Kimmig R; Schmid P Curr Opin Obstet Gynecol; 2007 Feb; 19(1):75-81. PubMed ID: 17218856 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]